

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_71274
Title of the Manuscript:	The Effects of Plasma Exchange on Diffuse Alveolar Hemorrhage in Severe Vasculitis – A Case Study
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>The usefulness of plasma exchange at the time of severe immunology diseases such as SLE, anti-GBM disease, etc is already confirmed. In addition, also several reports on the usefulness of plasma exchange in MPO-ANCA vasculitis are already published in the journals. Therefore, this article is not the first paper for the importance of plasma exchange in MPO-ANCA associated severe vasculitis. Besides, there are many inadequate expressions and mistakes for the medical descriptions.</p> <p>In Abstract,</p> <ol style="list-style-type: none"> 1) Life-threatening illness (DAH). Is this a correct expression? 2) HRCT: you should full spell out at the first description of HRCT. 3) Introduction, Case presentation, and Conclusion. Is it necessary to put one line space between Case presentation and Conclusion? <p>In Introduction and Case Report,</p> <ol style="list-style-type: none"> 1) The description styles of references are confusing throughout the manuscript. 2) In Table 1, no correct expression of g/dl, HCO₃⁻, TSH μIU/ml, etc. <p>In the Discussion,</p> <ol style="list-style-type: none"> 1) Line 4-5 says that "ANCA associated vasculitis is a multisystem disease with more than 75% of patients with renal involvement presenting with rapidly progressive glomerulonephritis." This is not true. Many patients present with mild renal involvement [1-3]. If you insist that your description is true, you must list up the articles for the reference. <ol style="list-style-type: none"> 1. Nakabayashi K. et al. Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience. Modern Rheumatol 2009; 19: 420-426. 2. Nakabayashi K. et al. Tubulointerstitial nephritis without glomerular lesions in three patients with myeloperoxidase-ANCA-associated vasculitis. Clin Exp Nephrol 2009; 13: 605-613. 3. Berden AE. Histopathologic classification of ANCA-associated glomerulonephritis. JASN 2010; 21: 1628-1636. 	
Minor REVISION comments		

Review Form 1.6

Optional/General comments		
----------------------------------	--	--

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	<i>Kimimasa Nakabayashi</i>
Department, University & Country	<i>Kyorin University, Japan</i>